CompaniesHealthcare & FitnessPharmaceuticalsPrint articleBrief: BionomicsBionomics will initiate the second Phase II clinical trial of vascular disrupting agent BNC105.Mar 26, 2010 – 11.52amSaveLog in or Subscribe to save articleShareCopy linkCopiedEmailLinkedInTwitterFacebookCopy linkCopiedShare via...Gift this articleSubscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? Login Bionomics will initiate the second Phase II clinical trial of vascular disrupting agent BNC105, this time in patients with advanced mesothelioma, a deadly asbestos-related cancer. It will involve 60 patients at 12 centres in Australia.Loading...SaveLog in or Subscribe to save articleShareCopy linkCopiedEmailLinkedInTwitterFacebookCopy linkCopiedShare via...Gift this articleSubscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? LoginLicense articleIntroducing your NewsfeedFollow the topics, people and companies that matter to you.Find out moreRead MorePharmaceuticalsBionomics LimitedLatest In Healthcare & fitnessFetching latest articlesMost Viewed In Companies
